<DOC>
	<DOC>NCT00134511</DOC>
	<brief_summary>The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol</brief_summary>
	<brief_title>Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder</brief_title>
	<detailed_description>For additional information please call: 1-800-718-1021</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<criteria>Diagnosis of Homozygous Familial Hypercholesterolemia Women who are pregnant or lactating, or planning to become pregnant. Subjects with a clinically indicated need for statin (HMGCoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDLC and HDLC including fibrates and nicotinic acid Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMGCoA reductase inhibitors Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>